Last reviewed · How we verify
Fexuprazan Hydrochloride
Fexuprazan hydrochloride is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.
Fexuprazan hydrochloride is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease.
At a glance
| Generic name | Fexuprazan Hydrochloride |
|---|---|
| Also known as | Fexuclue Tablet |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | Potassium-competitive acid blocker (P-CAB) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Unlike proton pump inhibitors (PPIs) that irreversibly bind to the H+/K+-ATPase, fexuprazan competitively blocks potassium binding to the pump, allowing for faster onset and offset of acid suppression. This mechanism provides rapid and sustained gastric pH elevation, making it effective for acid-related disorders. The reversible binding may offer advantages in terms of drug interactions and recovery of acid secretion.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
Key clinical trials
- Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids (PHASE4)
- A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
- Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
- Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fexuprazan Hydrochloride CI brief — competitive landscape report
- Fexuprazan Hydrochloride updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI